Trials / Completed
CompletedNCT03018028
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 243 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Oral administration once daily |
| DRUG | Placebo | Oral administration once daily |
| DRUG | Liraglutide | Subcutaneous (s.c., under the skin) injection once daily |
Timeline
- Start date
- 2017-01-10
- Primary completion
- 2018-01-09
- Completion
- 2018-08-15
- First posted
- 2017-01-11
- Last updated
- 2021-01-15
- Results posted
- 2019-12-30
Locations
16 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03018028. Inclusion in this directory is not an endorsement.